nach oben

Erschienen in:

10.03.2016 | Original Article

Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma

verfasst von: A. C. Mamede, S. Guerra, M. Laranjo, K. Santos, M. J. Carvalho, T. Carvalheiro, P. Moura, A. Paiva, A. M. Abrantes, C. J. Maia, M. F. Botelho

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

The anticancer effects of human amniotic membrane (hAM) have been studied over the last decade. However, the action mechanisms responsible for these effects are not fully understood until now. Previously results reported by our team proved that hAM is able to induce cytotoxicity and cell death in hepatocellular carcinoma (HCC), a worldwide high incident and mortal cancer. Therefore, this experimental study aimed to investigate the cellular targets of hAM protein extracts (hAMPE) in HCC through in vitro studies. Our results showed that hAMPE is able to modify oxidative stress environment in all HCC cell lines, as well as its cell cycle. hAMPE differently targets deoxyribonucleic acid (DNA), P21, P53, β-catenin and multidrug resistance (MDR) proteins in HCC cell lines. In conclusion, hAMPE has several targets in HCC, being clear that the success of this treatment depends of a personalized therapy based on the biological and genetic characteristics of the tumor.

Toda A, Okabe M, Yoshida T, Nikaido T (2007) The potential of amniotic membrane/amnion-derived cells for regeneration of various tissues. J Pharmacol Sci 105:215–228CrossRefPubMed

Davis J (1910) Skin transplantation with a review of 550 cases at the Johns Hopkins Hospital. Johns Hopkins Med J 15:307

Gomes J, Romano A, Santos M, Dua H (2005) Amniotic membrane use in ophthalmology. Curr Opin Ophthalmol 16:233–240CrossRefPubMed

Dua H, Azuara-Blanco A (1999) Amniotic membrane transplantation. Br J Ophthalmol 83:748–752CrossRefPubMedPubMedCentral

Sawhney C (1989) Amniotic membrane as a biological dressing in the management of burns. Burns 15:339–342CrossRefPubMed

Mamede A, Carvalho M, Abrantes A, et al. (2012) Amniotic membrane: from structure and functions to clinical applications. Cell Tissue Res 349:447–458CrossRefPubMed

Magatti M, De Munari S, Vertua E, Parolini O (2012) Amniotic membrane-derived cells inhibit proliferation of cancer cell lines by inducing cell cycle arrest. J Cell Mol Med 16:2208–2218CrossRefPubMedPubMedCentral

Jiao H, Guan F, Yang B, et al. (2012) Human amniotic membrane derived-mesenchymal stem cells induce C6 glioma apoptosis in vivo through the bcl-2/caspase pathways. Mol Biol Rep 39:467–473CrossRefPubMed

Rolfo A, Giuffrida D, Giuffrida M, et al. (2014) New perspectives for prostate cancer treatment: in vitro inhibition of LNCaP and PC3 cell proliferation by amnion-derived mesenchymal stromal cells conditioned media. Aging Male 17:94–101CrossRefPubMed

10.

Kang N-H, Yi B-R, Lim S, et al. (2012) Human amniotic membrane-derived epithelial stem cells display anticancer activity in BALB/c female nude mice bearing disseminated breast cancer xenografts. Int J Oncol 40:2022–2028PubMed

11.

Niknejad H, Khayat-Khoei M, Peirovi H, Abolghasemi H (2014) Human amniotic epithelial cells induce apoptosis of cancer cells: a new anti-tumor therapeutic strategy. Cytotherapy 16:33–40CrossRefPubMed

12.

Mamede A, Laranjo M, Carvalho M, et al. (2014) Effect of amniotic membrane proteins in human cancer cell lines: an exploratory study. J Membr Biol 247:357–360CrossRefPubMed

13.

Mamede A, Guerra S, Laranjo M, et al. (2015) Selective cytotoxicity and cell death induced by human amniotic membrane in hepatocellular carcinoma. Med Oncol 32:257CrossRefPubMed

14.

Gomes M, Priolli D, Tralhão J, Botelho M (2013) Hepatocellular carcinoma: epidemiology, biology, diagnosis and therapies. Rev Assoc Med Bras 59:514–524CrossRefPubMed

15.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403CrossRefPubMed

16.

Marra M, Sordelli I, Lombardi A, et al. (2011) Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 9:171CrossRefPubMedPubMedCentral

17.

Alves R, Alves D, Guz B, et al. (2011) Advanced hepatocellular carcinoma: review of targeted molecular drugs. Ann Hepatol 10:21–27PubMed

18.

Brito A, Abrantes A, Pinto-Costa C, et al. (2013) Hepatocellular carcinoma and chemotherapy: the role of p53. Chemotherapy 58:381–386CrossRef

19.

Tralhão J, Abrantes A, Hoti E, et al. (2013) Hepatectomy and liver regeneration: from experimental research to clinical application. ANZ J Surg 84:665–671CrossRefPubMed

20.

Abrantes A, Serra M, Gonçalves A, et al. (2010) Hypoxia-induced redox alterations and their correlation with 99mTc-MIBI and 99mTc-HL-91 uptake in colon cancer cells. Nucl Med Biol 37:125–132CrossRefPubMed

21.

Tralhão J, Abrantes A, Gonçalves A, et al. (2013) Study of hepatocellular function in the murine model following hepatic artery selective clamping. Acta Cir Bras 28:657–663CrossRefPubMed

22.

Gomes A, Fernandes E, Lima J (2005) Fluorescence probes used for detection of reactive oxygen species. J Biochem Biophys Methods 65:45–80CrossRefPubMed

23.

Mamede A, Pires A, Abrantes A, et al. (2012) Cytotoxicity of ascorbic acid in a human colorectal adenocarcinoma cell line (WiDr): in vitro and in vivo studies. Nutr Cancer 64:1049–1057CrossRefPubMed

24.

Larrauri A, López P, Gómez-Lechón M, Castell J (1987) A cytochemical stain for glutathione in rat hepatocytes cultured on plastic. J Histochem Cytochem 35:271–274CrossRefPubMed

25.

Ioannou Y, Chen F (1996) Quantitation of DNA fragmentation in apoptosis. Nucleic Acids Res 24:992–993CrossRefPubMedPubMedCentral

26.

Santos K, Laranjo M, Abrantes A, et al. (2014) Targeting triple-negative breast cancer cells with 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles. Eur J Med Chem 79:273–281CrossRefPubMed

27.

Serra A, Am RG, Laranjo M, et al. (2012) Synthesis of new 2-galactosylthiazolidine-4-carboxylic acid amides. antitumor evaluation against melanoma and breast cancer cells. Eur J Med Chem 53:398–402CrossRefPubMed

28.

Brito A, Abrantes A, Ribeiro M, et al. (2015) Fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma: correlation with glucose transporters and p53 expression. J Clin Exp Hepatol 5:183–189CrossRefPubMedPubMedCentral

29.

Gomes A, Abrantes A, Brito A, et al. (2015) P53 influence on the radiotherapy response of hepatocellular carcinoma. Clin Mol Hepatol 21:257–267CrossRefPubMedPubMedCentral

30.

Brito A, Mendes M, Abrantes A, et al. (2014) Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)fluoro-d-glucose. Mol Diagn Ther 18:495–504CrossRefPubMed

31.

Casalta-Lopes J, Abrantes A, Laranjo M, et al. (2011) Efflux pumps modulation in colorectal adenocarcinoma cell lines: the role of nuclear medicine. J Cancer Ther 02:408–417CrossRef

32.

Choi K, Kim J, Kim G, Choi C (2009) Oxidative stress-induced necrotic cell death via mitochondira-dependent burst of reactive oxygen species. Curr Neurovasc Res 6:213–222CrossRefPubMed

33.

Valko M, Leibfritz D, Moncol J, et al. (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44–84CrossRefPubMed

34.

Li Y, Schellhorn H (2007) New developments and novel therapeutic perspectives for vitamin C. J Nutr 137:2171–2184PubMed

35.

Georgiou C, Papapostolou I, Grintzalis K (2009) Protocol for the quantitative assessment of DNA concentration and damage (fragmentation and nicks). Nat Protoc 4:125–131CrossRefPubMed

36.

Reuter S, Gupta S, Chaturvedi M, Aggarwal B (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49:1603–1616CrossRefPubMedPubMedCentral

37.

Oberhammer F, Wilson J, Dive C, et al. (1993) Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12:3679–3684PubMedPubMedCentral

38.

Zamai L, Falcieri E, Marhefka G, Vitale M (1996) Supravital exposure to propidium iodide identifies apoptotic cells in the absence of nucleosomal DNA fragmentation. Cytometry 23:303–311CrossRefPubMed

39.

Macleod K, Sherry N, Hannon G, et al. (1995) p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935–944CrossRefPubMed

40.

Hussain S, Schwank J, Staib F, et al. (2007) TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26:2166–2176CrossRefPubMed

41.

Cayrol C, Knibiehler M, Ducommun B (1998) p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16:311–320CrossRefPubMed

42.

Punchihewa C, Inoue A, Hishiki A, et al. (2012) Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. J Biol Chem 287:14289–14300CrossRefPubMedPubMedCentral

43.

Stark G, Taylor W (2004) Analyzing the G2/M checkpoint. In: Schonthal AH (ed) Checkp. Control. cancer Rev. Model Syst. Humana Press, Totowa, pp. 51–82

44.

Wu G, Xu L, Lin N, Liu B (2013) UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1 or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines. BMC Cancer 13:167CrossRefPubMedPubMedCentral

45.

Chan K-T, Lung M (2004) Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 53:519–526CrossRefPubMed

46.

Tsang W-P, Chau S, Fung K-P, et al. (2003) Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in saos-2 cells. Cancer Chemother Pharmacol 51:161–166PubMed

Titel: Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma
verfasst von: A. C. Mamede
S. Guerra
M. Laranjo
K. Santos
M. J. Carvalho
T. Carvalheiro
P. Moura
A. Paiva
A. M. Abrantes
C. J. Maia
M. F. Botelho
Publikationsdatum: 10.03.2016
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 4/2016
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-016-0053-x

Springer Medizin

Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Trends in Gastrointestinal Cancer Mortality Rate in Hungary

Association between IL-6 Gene (−174 & -572 G/C) Polymorphisms and Endometrial Adenocarcinoma Risk

Long Non-Coding RNA lincRNA-ROR Promotes the Progression of Colon Cancer and Holds Prognostic Value by Associating with miR-145

Immunohistochemical Study EMT-Related Proteins in HPV-, and EBV-Negative Patients with Sinonasal Tumours

Relevance of the Measles Virus Expression in Cancer - an Update

Frameshift Mutation of MED25, a Transcription Regulator, and its Mutational Heterogeneity in Colorectal Cancers

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie